Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2162224 | 0.65 | CNR2 (0.39) | CNR2RPS6KB1CDK2MAPKAPK2GSK3B | |
| SCHEMBL3745498 | 0.64 | ABCC1 (0.51) | CNR2RPS6KB1CDK2MAPKAPK2GSK3B | |
| SCHEMBL4090736 | 0.64 | POLB (0.45) | CNR2RPS6KB1CDK2MAPKAPK2GSK3B | |
| SCHEMBL4091390 | 0.63 | RPS6KB1 (0.50) | CNR2RPS6KB1CDK2MAPKAPK2GSK3B | |
| SCHEMBL4091622 | 0.62 | PTPN1 (0.63) | — | |
| SCHEMBL4086799 | 0.62 | PTPN1 (0.63) | — | |
| SCHEMBL4085763 | 0.61 | CNR2 (0.43) | CNR2RPS6KB1CDK2MAPKAPK2GSK3B | |
| SCHEMBL4079889 | 0.60 | PTPN1 (0.66) | CNR2 | |
| SCHEMBL2163111 | 0.60 | CNR2 (0.46) | CNR2 | |
| SCHEMBL4090461 | 0.60 | CNR2 (0.70) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338623-B2 | N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885RPS6KB1 780/4885CDK2 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.